MedPath

Vaderis' VAD044 Receives FDA Fast Track Designation for Hereditary Hemorrhagic Telangiectasia

• Vaderis Therapeutics' VAD044, an allosteric AKT-inhibitor, has been granted Fast Track designation by the FDA for treating Hereditary Hemorrhagic Telangiectasia (HHT). • The FDA's Fast Track program aims to accelerate the development and review of drugs addressing serious conditions with unmet medical needs, potentially expediting VAD044's availability. • VAD044 is an oral, once-daily therapy and the first novel treatment specifically designed for HHT, a genetic bleeding disorder lacking approved treatments. • HHT is a rare, inherited bleeding disorder that causes significant disease burden, reduced life expectancy, and impaired quality of life, highlighting the need for effective therapies.

Vaderis Therapeutics AG has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for VAD044, an allosteric AKT-inhibitor, in the treatment of Hereditary Hemorrhagic Telangiectasia (HHT). This designation aims to expedite the development and review process for drugs treating serious conditions with unmet medical needs.
HHT is the second most common inherited bleeding disorder, often leading to severe health issues, reduced lifespan, and diminished quality of life. Currently, there are no approved treatments for HHT worldwide. VAD044 is an oral, once-daily allosteric AKT-inhibitor being developed as the first therapy specifically for HHT.

Significance of Fast Track Designation

The FDA's Fast Track program is designed to facilitate the development and accelerate the approval of drugs that address serious conditions and fulfill unmet medical needs, potentially bringing important new treatments to patients sooner.
Dr. Hanny Al-Samkari, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, commented on the designation, stating, "The FDA's decision to designate VAD044 as a Fast Track product for the treatment of HHT underscores its potential to be the first ever approved treatment for this debilitating genetic disease."

About VAD044 and Vaderis' Approach

Vaderis is focused on developing treatments for rare and orphan diseases associated with vascular malformations. Many of these diseases, including HHT, involve overactivation of AKT due to upstream genetic mutations, leading to excessive vascular growth. VAD044 is currently being evaluated in a 12-month Open Label Extension study, following a clinical proof-of-concept study in HHT patients. Vaderis aims to be the first company to develop a medicine for HHT and other diseases related to vascular malformations.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Star Therapeutics' VGA039 Receives FDA Fast Track Designation for Von Willebrand Disease

The FDA has granted Fast Track designation to Star Therapeutics' VGA039 for von Willebrand disease (VWD), potentially expediting its development.
VGA039, a monoclonal antibody targeting Protein S, aims to restore blood clotting balance and is designed as a convenient subcutaneous therapy.

AdAPT-001, EpicentRx's Oncolytic Virus-Delivered TGFβ Inhibitor, Receives FDA Fast Track Designation for Soft Tissue Sarcoma

The FDA has granted Fast Track designation to EpicentRx's AdAPT-001 for treating recurrent or refractory soft tissue sarcoma (STS).
AdAPT-001, delivered via an oncolytic adenovirus, inhibits transforming growth factor beta (TGFβ) and is used with nivolumab or atezolizumab.

Alkeus Pharmaceuticals' Gildeuretinol Receives FDA Fast Track and Rare Pediatric Disease Designations for Stargardt Disease

Gildeuretinol (ALK-001) receives Rare Pediatric Disease and Fast Track designations from the FDA, highlighting the urgent need for Stargardt disease treatments.
TEASE program data presented at the American Academy of Ophthalmology showed gildeuretinol slowed the growth rate of atrophic retinal lesions in Stargardt patients.

FDA Approves PTC Therapeutics' Gene Therapy Kebilidi for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi), a gene therapy developed by PTC Therapeutics, for treating AADC deficiency in adult and pediatric patients.
Kebilidi is the first FDA-approved gene therapy for AADC deficiency, a rare genetic disorder affecting neurotransmitter production and causing severe developmental delays.

FDA Approves Hympavzi (marstacimab-hncq) as Novel Treatment for Hemophilia A and B

The FDA has approved Hympavzi (marstacimab-hncq), a novel monoclonal antibody, for hemophilia A and B in patients 12 years and older.
Hympavzi offers a new mechanism by reducing tissue factor pathway inhibitor, enhancing thrombin production to facilitate blood clotting.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.
Kebilidi, developed by PTC Therapeutics, is the first gene therapy approved in the U.S. that is directly administered to the brain via a stereotactic surgical procedure.

FDA Approves Eladocagene Exuparvovec-Tneq (Kebilidi) for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Approval was based on a clinical trial of 13 pediatric patients, where 8 of 12 treated individuals showed improved gross motor function compared to untreated individuals.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in patients aged 18 months and older.
Kebilidi is the first gene therapy administered directly to the brain to be approved in the United States for this rare genetic disorder.

Vaderis' VAD044 Shows Promise in Hereditary Hemorrhagic Telangiectasia Trial

Vaderis Therapeutics' VAD044 demonstrated favorable safety and tolerability in a Phase 2 proof-of-concept trial for Hereditary Hemorrhagic Telangiectasia (HHT).
The trial showed clinically meaningful improvements in epistaxis frequency, duration, and epistaxis-free days in HHT patients treated with VAD044.

Vega Therapeutics' VGA039 Receives FDA Orphan Drug Designation for Von Willebrand Disease

Vega Therapeutics' VGA039, a first-in-class antibody, has been granted Orphan Drug Designation by the FDA for treating von Willebrand disease (VWD).
VGA039 modulates Protein S to enhance thrombin generation, addressing a core mechanism of clot formation in VWD.

Reference News

[1]
Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary ...
newswire.ca · Nov 18, 2024

Vaderis Therapeutics AG announces FDA Fast Track designation for VAD044, an AKT-inhibitor for Hereditary Hemorrhagic Tel...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy